Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Advanced Solid Tumor · Sjogren's Disease · CGEM

Cullinan Therapeutics

Cullinan Therapeutics clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Dyer St, Providence, Rhode Island 02903, US HQ
2017 Founded
7 Employees
Public company Type
CGEM · NYSE Ticker
Company details
Status
Public
HQ
Dyer St, Providence, Rhode Island 02903, US
Founded
2017
Employees
7
Programs
16
Drugs
14
Patents
3
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Cullinan Therapeutics projects

16 ClinicalTrials.gov programs sponsored by Cullinan Therapeutics.

Cullinan Therapeutics has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

16 programs

Clinical programs

  1. CLN-081

    Cullinan Therapeutics

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. CLN-081, CLN-081

    Cullinan Therapeutics

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 2 small molecule active

    1 trial

  3. VK-2019

    Cullinan Therapeutics

    Nasopharyngeal Carcinoma

    phase 2 small molecule terminated

    1 trial

  4. CLN-049

    Cullinan Therapeutics

    Relapsed/Refractory Acute Myeloid Leukemia (AML)

    phase 1 small molecule active

    1 trial

  5. CLN-049-002

    Cullinan Therapeutics

    Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)

    phase 1 other active

    1 trial

  6. CLN-617

    Cullinan Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  7. CLN-619

    Cullinan Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  8. CLN-619

    Cullinan Therapeutics

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  9. CLN-619-001

    Cullinan Therapeutics

    Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, breast cancer, gastrointestinal cancer

    phase 1 other active

    1 trial

  10. CLN-978

    Cullinan Therapeutics

    Sjögren

    phase 1 small molecule active

    1 trial

  11. CLN-978

    Cullinan Therapeutics

    Rheumatoid Arthritis (RA

    phase 1 small molecule active

    1 trial

  12. CLN-978

    Cullinan Therapeutics

    SLE

    phase 1 small molecule active

    1 trial

  13. CLN-978

    Cullinan Therapeutics

    NHL

    phase 1 small molecule active

    1 trial

  14. CLN-978-RA-101

    Cullinan Therapeutics

    Treatment-Refractory Rheumatoid Arthritis

    phase 1 other active

    1 trial

  15. CLN-978-SJ-101

    Cullinan Therapeutics

    Sjogren's Disease

    phase 1 other active

    1 trial

  16. CLN-978-SL-101

    Cullinan Therapeutics

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Cullinan Therapeutics have?

16 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.